IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the ...
Background: Public insurance for testing supplies for self-monitoring of blood glucose is highly variable across Canada. We sought to determine if insured patients were more likely than uninsured ...
Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, but research shows uneven insurance coverage of these tests and inconsistent ...
BRISBANE, Calif., July 18, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and ...
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...
As tests and screenings for chronic conditions improve, Connecticut residents will have better access after lawmakers passed legislation mandating health insurance plans cover biomarker tests starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results